US › Healthcare

HCW Biologics Inc (HCWB)

US · Healthcare · Biotechnology

$1.24+0.81%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$135,568

Revenue YoY

+1969.7%

Net profit

$-5.2M

EPS

$-10.10

EPS estimate

$-1.98

Net margin

-3,849.9%

EPS came in at -10.10 against a street estimate of -1.98 — a miss of 410.1%.

Key statistics

Market cap

$2.8M

Forward P/E

0.0

P/B

0.41

Book value

$4.59

EPS (TTM)

$-19.84

52-week high

$26.13

52-week low

$1.14

50-day MA

$2.42

200-day MA

$4.54

Beta

2.42

Analyst view

Analysts rate HCW Biologics Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $8.00.

Shareholding

Insiders

7.98%

Institutions

7.41%

Largest institutional holders

Fund	Stake
Jane Street Group LLC	0.39%
Citadel Advisors Llc	0.15%
HRT FINANCIAL LLC	0.10%
Vanguard Fiduciary Trust Co	0.05%
Tower Research Capital LLC	0.03%
Connective Capital Management LLC	0.02%
Vanguard Capital Management, LLC	0.01%
Golden State Wealth Management, LLC	0.01%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for HCW Biologics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.